Leading Players in the Taiwan Amlodipine Besylate Market | Top Companies & Insights 2026

Leading Players in the Taiwan Amlodipine Besylate Market

The Taiwan Amlodipine Besylate Market is formed by a combination of international pharmaceutical giants and local manufacturers, each vying for market share with a focus on product quality and innovation. Key players in the market include Pfizer Inc., Novartis AG, Viatris Inc., Standard Chem & Pharm Co., Ltd., and Yung Shin Pharmaceutical Ind. Co., Ltd.

Taiwan Amlodipine Besylate Market Overview

According to 6Wresearch, the Taiwan Amlodipine Besylate Market is growing, and the major factor contributing to this growth is the rising number of people suffering from hypertension and other heart related problems. Amlodipine Besylate is a calcium channel blocker and is used for the treatment of high blood pressure.

The growing demand for effective and cost-efficient treatment for these problems are the major factors for the evolution of the market. In addition, the focus on healthcare and the government's initiatives for the production of generic drugs are also increasing the growth of the market.

Competitive Landscape

The competitive landscape in the Taiwan Amlodipine Besylate industry is categorized by the presence of several multinational corporations and local pharmaceutical companies. The leading players use their vast distribution network and strong production capabilities to maintain their competitive advantage in the market. Simultaneously, research and development are also an important factor in the market, as companies seek to launch cost-effective products in the market.

Below is a list of leading players operating in the Taiwan Amlodipine Besylate Market:

1. Pfizer Taiwan

Pfizer is a dominant leader, with its flagship Norvasc brand being widely utilized in cardiology departments and private clinics across the island.

2. Standard Chem & Pharm Co., Ltd.

Standard Chem provides essential generic versions of amlodipine that form the backbone of chronic management for hypertension.

3. Yung Shin Pharmaceutical Ind. Co., Ltd.

Yung Shin is a major player in the cardiovascular segment, focusing on advanced calcium channel blockers and combination therapies.

4. Viatris Taiwan

Viatris maintains a strong presence through its diversified portfolio of off-patent branded cardiovascular medications and high-quality generic alternatives.

5. TTY Biopharm Company Limited

TTY Biopharm focuses on specialized delivery systems and biotechnology-driven pharmaceutical products, including high-efficacy cardiovascular solutions.

6. Synmosa Biopharma Corporation

Synmosa focuses on its cardiovascular drugs and respiratory therapies, offering combination drugs designed to prevent ischemic heart disease complications.

7. CCP Pharmaceutical (China Chemical & Pharmaceutical Co.)

CCP provides critical anti-anginal agents and is a leader in the R&D of novel circulatory system treatments and manufacturing standards.

8. Everest Pharmaceuticals (Taiwan)

Everest specializes in high-quality generic cardiovascular drugs and is active in distributing specialized heart disease therapies.

9. AstraZeneca Taiwan

AstraZeneca is a leading manufacturer and distributor that partners with local pharmacies to bring specialized antiplatelet tools and cardiovascular medications.

10. Sanofi Taiwan

Sanofi is a prominent international distributor that provides a wide range of industry-standard cardiovascular treatments and metabolic health solutions.

Leading Players in the Taiwan Amlodipine Besylate Market: FAQs